{
    "2021-04-19": [
        [
            {
                "time": "2021-04-19",
                "original_text": "恒瑞医药2020年营收同比增长19.09%",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "营收",
                        "同比增长"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-19",
                "original_text": "恒瑞医药发布2020年报：研发投入大手笔；抗肿瘤产品营收增逾44%",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "年报",
                        "研发投入",
                        "抗肿瘤",
                        "营收增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-19",
                "original_text": "恒瑞医药2020年业绩稳健增长 研发投入近50亿元",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "业绩增长",
                        "研发投入"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-19",
                "original_text": "恒瑞医药(600276.SH)一季度净利润升13.77%至14.97亿元",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "一季度",
                        "净利润",
                        "增长"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-19",
                "original_text": "恒瑞医药(600276.SH)2020年度净利润升18.78%至63.28亿元拟10送2派2元",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "年度",
                        "净利润",
                        "分红"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-19",
                "original_text": "恒瑞医药：一季度剔除股权激励费用影响净利润升24.24%研发费用大增62.26%",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "一季度",
                        "净利润",
                        "研发费用",
                        "增长"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-19",
                "original_text": "北向资金爆买逾160亿元，新能源汽车概念股获大幅加仓",
                "features": {
                    "keywords": [
                        "北向资金",
                        "新能源汽车",
                        "加仓"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "新能源汽车"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-04-19",
                "original_text": "机构抱团股大反攻！聪明资金埋伏一季报个股名单曝光",
                "features": {
                    "keywords": [
                        "机构抱团",
                        "一季报",
                        "个股名单"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-19",
                "original_text": "东吴证券 - 医药生物行业：第五批带量采购对恒瑞医药影响有限，仍坚定看好【行业研究】",
                "features": {
                    "keywords": [
                        "东吴证券",
                        "医药生物",
                        "带量采购",
                        "恒瑞医药"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}